|
|
|
|
| LEADER |
00000cam a2200000Mu 4500 |
| 001 |
EBOOKCENTRAL_ocn923265432 |
| 003 |
OCoLC |
| 005 |
20240329122006.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
151010s1900 dcu o 000 0 eng d |
| 040 |
|
|
|a EBLCP
|b eng
|e pn
|c EBLCP
|d OCLCQ
|d MERUC
|d ZCU
|d ICG
|d OCLCO
|d OCLCF
|d OCLCQ
|d DKC
|d AU@
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|d OCLCL
|
| 020 |
|
|
|a 9780309573443
|
| 020 |
|
|
|a 0309573440
|
| 029 |
1 |
|
|a DEBBG
|b BV044107372
|
| 035 |
|
|
|a (OCoLC)923265432
|
| 050 |
|
4 |
|a RC848.H44R
|
| 082 |
0 |
4 |
|a 615
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Staff, Institute of Medicine.
|
| 245 |
1 |
0 |
|a Review of the Fialuridine (FIAU) Clinical Trials.
|
| 260 |
|
|
|a Washington :
|b National Academies Press,
|c 1900.
|
| 300 |
|
|
|a 1 online resource (280 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a ""Review of the Fialuridine (FIAU) Clinical Trials""; ""Copyright""; ""Preface""; ""Contents""; ""Executive Summary""; ""INTRODUCTION""; ""CLINICAL TRIALS""; ""HEPATITIS B AND OTHER VIRAL DISEASES""; ""EARLY CLINICAL TRIALS OF FIAC AT MEMORIAL SLOAN-KETTERING CANCER CENTER""; ""OCLASSEN CLINICAL TRIAL R89-001-01""; ""OCLASSEN CLINICAL TRIAL R90-001-01""; ""OCLASSEN CLINICAL TRIAL R-91-010""; ""ELI LILLY CLINICAL TRIAL H3X-MC-PPPA""; ""ELI LILLY TRIAL H3X-LC-PPPG""; ""ELI LILLY TRIAL H3X-MC-PPPC (NIH PROTOCOL #93-DK-0031)""; ""PATIENT INTERVIEWS""; ""OVERALL ASSESSMENT OF THE TRIALS""
|
| 505 |
8 |
|
|a ""REVIEW OF THE FDA TASK FORCE REPORT""""REVIEW OF THE NIH REPORT""; ""FDA-PROPOSED CHANGES TO THE CODE OF FEDERAL REGULATIONS""; ""ANCILLARY ISSUES""; ""CONCLUSIONS""; ""RECOMMENDATIONS""; ""Generic Issues""; ""Trial Design""; ""Adverse Event Reporting""; ""Compliance Audits""; ""Further Research Into FIAU Toxicity""; ""1 Introduction ""; ""GENESIS OF THIS STUDY""; ""CHARGE TO THE COMMITTEE""; ""METHODS AND PROCEDURE""; ""PLAN OF THE REPORT""; ""2 Clinical Trials ""; ""IMPORTANCE OF CLINICAL TRIALS""; ""THE RISK-BENEFIT NATURE OF TRIALS""; ""THE DRUG DEVELOPMENT PROCESS""; ""SAFETY REPORTS""
|
| 505 |
8 |
|
|a ""ETHICAL CONSIDERATIONS""""Procedural Requirements""; ""Substantive Norms""; ""A Favorable Balance of Harms and Benefits""; ""Equitable Selection of Subjects""; ""Compensation for Research-Related Injury""; ""Informed Consent""; ""SUMMARY""; ""3 Hepatitis B and Other Viral Diseases ""; ""NATURE OF CHRONIC VIRAL DISEASES""; ""NATURAL HISTORY OF CHRONIC HBV INFECTION""; ""NEED FOR ORALLY ACTIVE AGENTS""; ""THE FLARE PHENOMENON""; ""TOXIC EFFECTS OF OTHER NUCLEOSIDE ANALOGS""; ""SUMMARY""; ""4 Clinical Trials of FIAC at Memorial Sloan-Kettering Cancer Center ""
|
| 505 |
8 |
|
|a ""PHASE I EVALUATION OF FIAC IN IMMUNOSUPPRESSED PATIENTS WITH HERPESVIRUS INFECTION""""Comment""; ""PHASE I STUDY OF AIDS PATIENTS WITH PRESUMPTIVE OR PROVEN HERPESGROUP VIRUS INFECTION""; ""Comment""; ""PHASE I STUDY OF FIAC IN BONE MARROW TRANSPLANT PATIENTS WITH HERPESGROUP VIRUS INFECTIONS""; ""Comment""; ""PHASE I ORAL DOSE RANGING FIAC STUDY IN IMMUNOCOMPROMISED PATIENTSWITH VZV AND HSV INFECTIONS""; ""Comment""; ""PHASE I/II TRIAL OF FIAC EFFICACY IN IMMUNOSUPPRESSED PATIENTS WITHVZV INFECTION""; ""Comment""; ""SUMMARY OF ALL THE FIAC CLINICAL STUDIES AT MSKC""
|
| 505 |
8 |
|
|a ""5 Oclassen Clinical Trial R89-001-01""""COMMENT""; ""6 Oclassen Clinical Trial R90-001-01 (NIH Protocol 91-AI-0031) ""; ""COMMENT""; ""7 Oclassen Clinical Trial R91-001-10 (NIH Protocol 91-DK-AI-213) ""; ""COMMENT""; ""8 Eli Lilly Trial H3X-MC-PPPA ""; ""UNIVERSITY OF TEXAS, GALVESTON SITE""; ""TUFTS NEW ENGLAND MEDICAL CENTER SITE""; ""9 Eli Lilly Trial H3X-MC-PPPG ""; ""COMMENT""; ""10 Eli Lilly Trial H3X-MC-PPPC (NIH Protocol 93-DK-0031) ""; ""AVAILABLE CLINICAL DATA REGARDING POTENTIAL TOXICITY""; ""AVAILABLE SAFETY DATA""; ""DEVELOPMENT OF PROTOCOL AND FDA REVIEW""
|
| 500 |
|
|
|a ""Patient selection and enrollment""
|
| 590 |
|
|
|a ProQuest Ebook Central
|b Ebook Central Academic Complete
|
| 650 |
|
0 |
|a Hepatitis B
|x Chemotherapy
|x Evaluation.
|
| 650 |
|
0 |
|a Fialuridine
|x Testing.
|
| 650 |
|
0 |
|a Fiacitabine
|x Testing.
|
| 650 |
|
0 |
|a Clinical trials
|x Safety measures.
|
| 650 |
|
6 |
|a Hépatite B
|x Chimiothérapie
|x Évaluation.
|
| 650 |
|
6 |
|a Études cliniques
|x Sécurité
|x Mesures.
|
| 650 |
|
7 |
|a Clinical trials
|x Safety measures
|2 fast
|
| 650 |
|
7 |
|a Fiacitabine
|x Testing
|2 fast
|
| 650 |
|
7 |
|a Fialuridine
|x Testing
|2 fast
|
| 758 |
|
|
|i has work:
|a Review of the Fialuridine (FIAU) clinical trials (Text)
|1 https://id.oclc.org/worldcat/entity/E39PCFtqFk9KDgTdY4wdFhy9Tb
|4 https://id.oclc.org/worldcat/ontology/hasWork
|
| 776 |
0 |
8 |
|i Print version:
|a Staff, Institute of Medicine.
|t Review of the Fialuridine (FIAU) Clinical Trials.
|d Washington : National Academies Press, ©1900
|z 9780309052795
|
| 856 |
4 |
0 |
|u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=3376667
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3376667
|
| 994 |
|
|
|a 92
|b IZTAP
|
